vs

Side-by-side financial comparison of AMC Networks Inc. (AMCX) and DENTSPLY SIRONA Inc. (XRAY). Click either name above to swap in a different company.

DENTSPLY SIRONA Inc. is the larger business by last-quarter revenue ($961.0M vs $594.8M, roughly 1.6× AMC Networks Inc.). AMC Networks Inc. runs the higher net margin — -9.3% vs -15.2%, a 5.9% gap on every dollar of revenue. On growth, DENTSPLY SIRONA Inc. posted the faster year-over-year revenue change (6.2% vs -0.8%). DENTSPLY SIRONA Inc. produced more free cash flow last quarter ($60.0M vs $40.4M). Over the past eight quarters, DENTSPLY SIRONA Inc.'s revenue compounded faster (0.4% CAGR vs -0.1%).

AMC Networks Inc. is an American independent mass media and entertainment corporation headquartered in 11 Penn Plaza, New York City. The company owns and operates the eponymous cable channel, BBC America, IFC, Sundance TV, and We TV. It also owns the art house movie theater IFC Center in New York City; the independent film companies Independent Film Company and RLJE Films, the anime licensor Sentai Filmworks, the premium subscription streaming services AMC+, IFC Films Unlimited, Acorn TV, All...

Dentsply Sirona Inc. is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries. It has factories in 21 countries. The present company is largely the result of a merger in 1993 in which Gendex Corporation acquired Dentsply International Inc. for $590 million.

AMCX vs XRAY — Head-to-Head

Bigger by revenue
XRAY
XRAY
1.6× larger
XRAY
$961.0M
$594.8M
AMCX
Growing faster (revenue YoY)
XRAY
XRAY
+6.9% gap
XRAY
6.2%
-0.8%
AMCX
Higher net margin
AMCX
AMCX
5.9% more per $
AMCX
-9.3%
-15.2%
XRAY
More free cash flow
XRAY
XRAY
$19.6M more FCF
XRAY
$60.0M
$40.4M
AMCX
Faster 2-yr revenue CAGR
XRAY
XRAY
Annualised
XRAY
0.4%
-0.1%
AMCX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AMCX
AMCX
XRAY
XRAY
Revenue
$594.8M
$961.0M
Net Profit
$-55.5M
$-146.0M
Gross Margin
49.7%
46.1%
Operating Margin
-8.6%
-14.5%
Net Margin
-9.3%
-15.2%
Revenue YoY
-0.8%
6.2%
Net Profit YoY
80.5%
66.0%
EPS (diluted)
$-0.97
$-0.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMCX
AMCX
XRAY
XRAY
Q4 25
$594.8M
$961.0M
Q3 25
$561.7M
$904.0M
Q2 25
$600.0M
$936.0M
Q1 25
$555.2M
$879.0M
Q4 24
$599.3M
$905.0M
Q3 24
$599.6M
$951.0M
Q2 24
$625.9M
$984.0M
Q1 24
$596.5M
$953.0M
Net Profit
AMCX
AMCX
XRAY
XRAY
Q4 25
$-55.5M
$-146.0M
Q3 25
$76.5M
$-427.0M
Q2 25
$50.3M
$-45.0M
Q1 25
$18.0M
$20.0M
Q4 24
$-284.5M
$-430.0M
Q3 24
$41.4M
$-494.0M
Q2 24
$-29.2M
$-4.0M
Q1 24
$45.8M
$18.0M
Gross Margin
AMCX
AMCX
XRAY
XRAY
Q4 25
49.7%
46.1%
Q3 25
48.2%
48.8%
Q2 25
52.7%
52.4%
Q1 25
51.8%
53.0%
Q4 24
51.2%
49.3%
Q3 24
52.0%
52.1%
Q2 24
55.2%
51.9%
Q1 24
54.5%
53.1%
Operating Margin
AMCX
AMCX
XRAY
XRAY
Q4 25
-8.6%
-14.5%
Q3 25
9.9%
-24.1%
Q2 25
10.7%
-13.7%
Q1 25
11.6%
7.2%
Q4 24
-42.4%
-56.2%
Q3 24
15.6%
-48.6%
Q2 24
1.7%
5.1%
Q1 24
18.5%
4.4%
Net Margin
AMCX
AMCX
XRAY
XRAY
Q4 25
-9.3%
-15.2%
Q3 25
13.6%
-47.2%
Q2 25
8.4%
-4.8%
Q1 25
3.3%
2.3%
Q4 24
-47.5%
-47.5%
Q3 24
6.9%
-51.9%
Q2 24
-4.7%
-0.4%
Q1 24
7.7%
1.9%
EPS (diluted)
AMCX
AMCX
XRAY
XRAY
Q4 25
$-0.97
$-0.74
Q3 25
$1.38
$-2.14
Q2 25
$0.91
$-0.22
Q1 25
$0.34
$0.10
Q4 24
$-6.23
$-2.09
Q3 24
$0.76
$-2.46
Q2 24
$-0.66
$-0.02
Q1 24
$1.03
$0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMCX
AMCX
XRAY
XRAY
Cash + ST InvestmentsLiquidity on hand
$502.4M
$326.0M
Total DebtLower is stronger
$1.8B
$2.3B
Stockholders' EquityBook value
$981.9M
$1.3B
Total Assets
$3.9B
$5.4B
Debt / EquityLower = less leverage
1.78×
1.70×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMCX
AMCX
XRAY
XRAY
Q4 25
$502.4M
$326.0M
Q3 25
$716.8M
$363.0M
Q2 25
$866.4M
$359.0M
Q1 25
$870.2M
$398.0M
Q4 24
$784.6M
$272.0M
Q3 24
$816.4M
$296.0M
Q2 24
$802.6M
$279.0M
Q1 24
$690.5M
$291.0M
Total Debt
AMCX
AMCX
XRAY
XRAY
Q4 25
$1.8B
$2.3B
Q3 25
$1.9B
Q2 25
$2.2B
Q1 25
$2.3B
Q4 24
$2.3B
$1.7B
Q3 24
$2.3B
Q2 24
$2.4B
Q1 24
$2.3B
Stockholders' Equity
AMCX
AMCX
XRAY
XRAY
Q4 25
$981.9M
$1.3B
Q3 25
$1.1B
$1.5B
Q2 25
$971.7M
$2.0B
Q1 25
$888.8M
$2.0B
Q4 24
$855.6M
$1.9B
Q3 24
$1.1B
$2.5B
Q2 24
$1.1B
$3.1B
Q1 24
$1.1B
$3.3B
Total Assets
AMCX
AMCX
XRAY
XRAY
Q4 25
$3.9B
$5.4B
Q3 25
$4.2B
$5.7B
Q2 25
$4.4B
$6.1B
Q1 25
$4.3B
$6.0B
Q4 24
$4.4B
$5.8B
Q3 24
$4.8B
$6.6B
Q2 24
$4.9B
$6.9B
Q1 24
$4.9B
$7.1B
Debt / Equity
AMCX
AMCX
XRAY
XRAY
Q4 25
1.78×
1.70×
Q3 25
1.82×
Q2 25
2.27×
Q1 25
2.62×
Q4 24
2.73×
0.90×
Q3 24
2.10×
Q2 24
2.26×
Q1 24
2.17×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMCX
AMCX
XRAY
XRAY
Operating Cash FlowLast quarter
$49.2M
$101.0M
Free Cash FlowOCF − Capex
$40.4M
$60.0M
FCF MarginFCF / Revenue
6.8%
6.2%
Capex IntensityCapex / Revenue
1.5%
4.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$272.4M
$104.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMCX
AMCX
XRAY
XRAY
Q4 25
$49.2M
$101.0M
Q3 25
$44.8M
$79.0M
Q2 25
$102.8M
$48.0M
Q1 25
$108.8M
$7.0M
Q4 24
$58.1M
$87.0M
Q3 24
$62.2M
$141.0M
Q2 24
$104.4M
$208.0M
Q1 24
$150.9M
$25.0M
Free Cash Flow
AMCX
AMCX
XRAY
XRAY
Q4 25
$40.4M
$60.0M
Q3 25
$42.0M
$40.0M
Q2 25
$95.7M
$16.0M
Q1 25
$94.2M
$-12.0M
Q4 24
$37.6M
$36.0M
Q3 24
$53.9M
$98.0M
Q2 24
$95.2M
$156.0M
Q1 24
$144.1M
$-9.0M
FCF Margin
AMCX
AMCX
XRAY
XRAY
Q4 25
6.8%
6.2%
Q3 25
7.5%
4.4%
Q2 25
16.0%
1.7%
Q1 25
17.0%
-1.4%
Q4 24
6.3%
4.0%
Q3 24
9.0%
10.3%
Q2 24
15.2%
15.9%
Q1 24
24.2%
-0.9%
Capex Intensity
AMCX
AMCX
XRAY
XRAY
Q4 25
1.5%
4.3%
Q3 25
0.5%
4.3%
Q2 25
1.2%
3.4%
Q1 25
2.6%
2.2%
Q4 24
3.4%
5.6%
Q3 24
1.4%
4.5%
Q2 24
1.5%
5.3%
Q1 24
1.1%
3.6%
Cash Conversion
AMCX
AMCX
XRAY
XRAY
Q4 25
Q3 25
0.59×
Q2 25
2.04×
Q1 25
6.03×
0.35×
Q4 24
Q3 24
1.50×
Q2 24
Q1 24
3.29×
1.39×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMCX
AMCX

Subscription And Circulation$314.8M53%
Advertising$124.9M21%
Other$79.1M13%
License$74.8M13%
Related Party$1.2M0%

XRAY
XRAY

Essential Dental Solutions$372.0M39%
Equipment And Instruments$160.0M17%
Implants And Prosthetics$150.0M16%
CADCAM$139.0M14%
Wellspect Healthcare$88.0M9%
Orthodontics$52.0M5%

Related Comparisons